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Abstract omitted
P-2
Some practical considerations in the design of multi-arm multi-
stage designs
Jerome Wulff, Nikolaos Demiris
Cambridge Clinical Trial Unit, Cambridge, United Kingdom
Trials 2019, 20(Suppl 1):P-2
Introduction: In the design of cancer clinical trials, one is often con-
cerned with a number of options in the event that several treatments
are of interest.
Methods: We explore in this work the distinct possibilities when four
treatments are available, one acting as control and three as poten-
tially efficacious alternatives. This design may be embedded within
the context of multi-arm multi-stage (MAMS) trials where one may
select a two- or three-stage design.
Potential Results: We explore the application of such designs, in-
cluding trade-offs between potential gains in the number of pa-
tients with additional stages contrasted with patients “lost” due
to practical considerations such as patients randomised in
dropped arms while waiting for interim analyses and inspection
by an Independent Data and Safety Committee. In addition, in
cancer studies one may focus on the primary end-point using a
time-to-event analysis or a binary outcome by looking at the
probability of (potentially progression-free) survival at a specific,
clinically meaningful, time point. The effect of such choices is ex-
tensively investigated.
Potential Relevance & Impact: We conclude with a discussion of the
available software for MAMS designs and their advantages and dis-
advantages in terms of accuracy.
P-3
The UK plasma based Molecular profiling of Advanced breast cancer
to inform Therapeutic CHoices (plasmaMATCH) Trial: A multiple
parallel-cohort, phase IIa platform trial aiming to provide proof of
principle efficacy for designated targeted therapies in patient
subgroups identified through ctDNA screening (CRUK/15/010)
Sarah Kernaghan1, Laura Moretti1, Lucy Kilburn1, Katie Wilkinson1, Claire
Snowdon1, James Morden1, Iain Macpherson2, Andrew Wardley3,
Rebecca Roylance4, Richard Baird5, Alistair Ring6, Nicholas Turner7,
Judith M Bliss1, on behalf of the plasmaMATCH Trial Management
Group
1Clinical Trials and Statistics Unit at The Institute of Cancer Research
(ICR-CTSU), United Kingdom; 2The Beatson West of Scotland Cancer
Centre, Glasgow, United Kingdom; 3The Christie NHS Foundation Trust,
Manchester, United Kingdom; 4University College London Hospitals NHS
Foundation Trust, London, United Kingdom; 5Cambridge University
Hospitals NHS Foundation Trust, Cambridge, United Kingdom; 6The
Royal Marsden NHS Foundation Trust, Sutton, United Kingdom; 7The
Institute of Cancer Research and The Royal Marsden NHS Foundation
Trust, London, United Kingdom
Trials 2019, 20(Suppl 1):P-3
Introduction: plasmaMATCH is a novel platform trial which assesses
the potential of circulating tumour DNA (ctDNA) screening to dir-
ect targeted therapies in advanced breast cancer (ABC) patients.
The trial recruited ahead of target and will report initial results
within 3years of first patient first visit demonstrating efficiency of
this design.
Methods: plasmaMATCH is an open-label, multi-centre phase IIa plat-
form trial, consisting of a ctDNA screening component and five paral-
lel treatment cohorts. Patients with an actionable mutation identified
at ctDNA screening are invited to enter Cohorts A-D to receive a tar-
geted treatment matched to the mutation identified (A: ESR1–ex-
tended-dose fulvestrant; B: HER2–neratinib+/-fulvestrant; C&D: AKT1
(or PTEN for Cohort D) –AZD5363+/-fulvestrant). Cohort E was added
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Methods: Many pilot trials adopt a ‘traffic light’ system for evaluating
progression to the main trial determined by a set of criteria set up a
priori. We can set up a hypothesis-testing approach focused around
this system that tests against being in the RED zone (unacceptable
outcome) based on an expectation of being in the GREEN zone (ac-
ceptable outcome).
Results. For example, in relation to treatment fidelity, if we assume
the upper boundary of the RED zone is 40% and the lower bound of
the GREEN zone is 70% (designating unacceptable/acceptable treat-
ment fidelity, respectively), the sample size required for analysis
given 90% power and one-sided 5% alpha would be n=22 (interven-
tion group alone). A larger sample size would increase the power to
reject the RED signal in favour of potential progression.
Discussion: In general, more than one key process outcomes are
assessed for progression to a main trial; a composite approach would
be to appraise the rules of progression across all these key outcomes.
This methodology begins to provide a formal framework for
hypothesis-testing and sample size indication around process out-
come evaluation for pilot RCTs.
PS4B
- O1 Considerations concerning the use of health economics in the
design and analysis of adaptive clinical trials – a qualitative study
Laura Flight1, Daniel Hind1, Steven Julious1, Alan Brennan1, Susan Todd2
1University of Sheffield, United Kingdom; 2University of Reading, United
Kingdom
Trials 2019, 20(Suppl 1):PS4B
Introduction: Both adaptive designs and health economics offer in-
novative approaches to efficient research and decision making.
Adaptive designs allow data to be examined as a trial progresses to
inform changes to that trial. The methods of health economics aim
to maximise the health gained for the money spent. Methods for
evaluating cost-effectiveness could be incorporated into the design
and analysis of adaptive clinical trials, to give innovative and efficient
trials.
Methods: A qualitative study explored the attitudes of key stake-
holders – including researchers, decision makers and members of the
public - towards the use of health economics in the design, monitor-
ing and analysis of adaptive clinical trials. Data were collected using
interviews and focus groups. Framework analysis was used to analyse
the data and identify themes.
Results: Twenty-nine participants took part in the study. Partici-
pants considered that answering the clinical research question
should be the priority in a clinical trial, despite their awareness
that cost-effectiveness was important for decision making. Con-
cerns raised by participants included: handling the volatile nature
of cost data at interim cost-effectiveness analyses; implementing
this approach in global trials; resourcing the development of
adaptive trial designs that use health economics in their design
and analysis and training stakeholders in these methods so that
they can be implemented by researchers and appropriately inter-
preted by decision makers.
Conclusion: The use of health economics in the design and analysis
of adaptive clinical trials has the potential to increase the efficiency
of health technology assessments worldwide. However, careful con-
sideration is needed to ensure the statistical methods reflect the im-
portance of clinical effectiveness and adequate training and
resources are provided to facilitate the implementation of this
approach.
PS4B
- O2 Stopping a clinical trial early based on the probability that
cost-effectiveness is unlikely: An extension of conditional power
computations to economic evaluation
iftekhar Khan
University of Oxford, Oxford, United Kingdom
Trials 2019, 20(Suppl 1):PS4B
Introduction: Conditional power (CP) is a well-established method
for conducting futility analyses in clinical trials to stop a trial early for
lack of efficacy using observed data at some interim point. However,
despite futility criteria not being met, a trial may continue with mod-
est efficacy gains that are unlikely to be cost-effective. Treatment ef-
fects from such trials may not offer value for money to tax payers
because the cost per quality adjusted life year (QALY) can be much
higher than acceptable thresholds. Stopping a trial based on the
joint criteria of efficacy and costs have not been examined in detail.
Objectives: We extend the conditional power computations and
examine the probability of cost-effectiveness conditional on the data
observed at some interim point when applied in practice.
Methods: Expressions for the conditional power based on efficacy for
the two sample case (1:1 allocation) are extended to cost-
effectiveness. The incremental net benefit (INB), willingness to pay
(WTP) threshold, interim and final sample sizes, variabilities and cor-
relations between costs and effects are examined. Data from several
clinical trials are used to examine the operating characteristics of the
conditional power of cost-effectiveness (CPCE).
Results (TBC): Both CP and CPCE agree in general, about 70% of the
time for a CP threshold of 80%. CPCE conclusions will differ and can
be much lower 30% of the time, depending on the WTP. Hence, trials
may continue based on clinical efficacy, despite interventions being
unlikely to be cost-effective. Value of information methods (VOI) and
Bayesian predictive power results provide consistent conclusions
with CPCE.
Conclusions: CP based on cost-effectiveness is feasible and a useful
tool during IDMC meetings (where health economists are increas-
ingly involved) for decision making, especially where clinical effects
are modest or small. CPCE uses more information than standard CP
methods and is more informative.
PS4B
- O3 Cost-Effective Clinical Trial Design: Application of a Bayesian
Sequential Stopping Rule to the ProfHER Pragmatic Trial
Martin Forster1, Stephen Brealey1, Stephen Chick2, Ada Keding1, Belen
Corbacho1, Andres Alban2, Amar Rangan1,3,4
1University Of York, York, United Kingdom; 2INSEAD, Fontainebleau,
France; 3University of Oxford, Oxford, United Kingdom; 4James Cook
University Hospital, Middlesbrough, United Kingdon
Trials 2019, 20(Suppl 1):PS4B
Introduction: We investigate value-based, sequential, clinical trial de-
sign by applying a Bayesian decision-theoretic model of a sequential
experiment to data from the ProfHER pragmatic trial. The work repre-
sents the first applied analysis of this value-based, sequential, design
to retrospective data from a completed clinical trial.
Methods: We take information on the research cost profile from the
trial and incorporate information on the accumulation of evidence
on cost-effectiveness to obtain a stopping boundary. We compare
this with the accumulation of data in the trial itself and use a boot-
strap analysis to study the stopping rule's operating characteristics.
Results: We show that the model's stopping policy would have
stopped the trial early, saving about 5% of the research budget
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